MyCAF-derived Exosomal PWAR6 Accelerates CRC Liver Metastasis Via Altering Glutamine Availability and NK Cell Function in the Tumor Microenvironment

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2024 Dec 19

PMID 39696364

Authors

Hongsheng Fang

Weixing Dai

Ruiqi Gu

Yanbo Zhang

Jin Li

Wenqin Luo

Shanyou Tong

Lingyu Han

Yichao Wang

Chengyao Jiang

Xue Wang

Renjie Wang

Guoxiang Cai

Affiliations

Soon will be listed here.

Abstract

Background: Liver metastasis from colorectal cancer (CRC) is a major clinical challenge that severely affects patient survival. myofibroblastic cancer-associated fibroblasts (myCAFs) are a major component of the CRC tumor microenvironment, where they contribute to tumor progression and metastasis through exosomes.

Methods: Single-cell analysis highlighted a notable increase in myCAFs in colorectal cancer liver metastases (CRLM). Exosomal sequencing identified PWAR6 as the most significantly elevated lncRNA in these metastatic tissues. In vivo and in vitro assays confirmed PWAR6's roles in CRC cell stemness, migration, and glutamine uptake. RNA pulldown, RIP, and Co-IP assays investigated the molecular mechanisms of the PWAR6/NRF2/SLC38A2 signaling axis in CRC progression, flow cytometry was used to assess NK cell activity and cytotoxicity.

Results: Clinically, higher PWAR6 expression levels are strongly associated with increased Ga FAPI-PET/CT SUVmax values, particularly in CRLM patients, where expression significantly exceeds that of non-LM cases and normal colon tissues. Regression analysis and survival data further support PWAR6 as a negative prognostic marker, with elevated levels correlating with worse patient outcomes. Mechanistically, PWAR6 promotes immune evasion by inhibiting NRF2 degradation through competitive binding with Keap1, thereby upregulating SLC38A2 expression, which enhances glutamine uptake in CRC cells and depletes glutamine availability for NK cells.

Conclusion: myCAFs derived exosomes PWAR6 represents a pivotal marker for CRC liver metastasis, and its targeted inhibition with ASO-PWAR6, in combination with FAPI treatment, effectively curtails metastasis in preclinical models, offering promising therapeutic potential for clinical management.

References

Hu J, Wang W, Lan X, Zeng Z, Liang Y, Yan Y . CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019; 18(1):91. PMC: 6503554. DOI: 10.1186/s12943-019-1019-x. View

Siegel R, Giaquinto A, Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):12-49. DOI: 10.3322/caac.21820. View

Ji Q, Zhou L, Sui H, Yang L, Wu X, Song Q . Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation. Nat Commun. 2020; 11(1):1211. PMC: 7058049. DOI: 10.1038/s41467-020-14869-x. View

Adinolfi S, Patinen T, Deen A, Pitkanen S, Harkonen J, Kansanen E . The KEAP1-NRF2 pathway: Targets for therapy and role in cancer. Redox Biol. 2023; 63:102726. PMC: 10189287. DOI: 10.1016/j.redox.2023.102726. View

Zhang C, Zhang B . RNA therapeutics: updates and future potential. Sci China Life Sci. 2022; 66(1):12-30. PMC: 9470505. DOI: 10.1007/s11427-022-2171-2. View

Cruzat V, Rogero M, Keane K, Curi R, Newsholme P . Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients. 2018; 10(11). PMC: 6266414. DOI: 10.3390/nu10111564. View

Liu T, Han C, Fang P, Ma Z, Wang X, Chen H . Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma. J Hematol Oncol. 2022; 15(1):141. PMC: 9548164. DOI: 10.1186/s13045-022-01359-4. View

Yang E, Wang X, Gong Z, Yu M, Wu H, Zhang D . Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther. 2020; 5(1):242. PMC: 7572387. DOI: 10.1038/s41392-020-00359-5. View

Li N, Lu B, Luo C, Cai J, Lu M, Zhang Y . Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America. Cancer Lett. 2021; 522:255-268. DOI: 10.1016/j.canlet.2021.09.034. View

10.

Wu S, Fu T, Jiang Y, Shao Z . Natural killer cells in cancer biology and therapy. Mol Cancer. 2020; 19(1):120. PMC: 7409673. DOI: 10.1186/s12943-020-01238-x. View

11.

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

12.

Li B, Cao Y, Meng G, Qian L, Xu T, Yan C . Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 2018; 39:239-254. PMC: 6355660. DOI: 10.1016/j.ebiom.2018.11.063. View

13.

Li H, Dai W, Xia X, Wang R, Zhao J, Han L . Modeling tumor development and metastasis using paired organoids derived from patients with colorectal cancer liver metastases. J Hematol Oncol. 2020; 13(1):119. PMC: 7650218. DOI: 10.1186/s13045-020-00957-4. View

14.

Wong C, Xu J, Bian X, Wu J, Kang W, Qian Y . In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. Gastroenterology. 2020; 159(6):2163-2180.e6. DOI: 10.1053/j.gastro.2020.08.016. View

15.

Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E . In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer. 2019; 146(4):895-905. PMC: 6972582. DOI: 10.1002/ijc.32193. View

16.

Maskalenko N, Zhigarev D, Campbell K . Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022; 21(8):559-577. PMC: 10019065. DOI: 10.1038/s41573-022-00413-7. View

17.

Ramasamy T, Ruttala H, Munusamy S, Chakraborty N, Kim J . Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. J Control Release. 2022; 352:861-878. DOI: 10.1016/j.jconrel.2022.10.050. View

18.

Tran T, Hanse E, Habowski A, Li H, Ishak Gabra M, Yang Y . α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer. Nat Cancer. 2020; 1(3):345-358. PMC: 7442208. DOI: 10.1038/s43018-020-0035-5. View

19.

Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M . CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014; 14(3):342-56. DOI: 10.1016/j.stem.2014.01.009. View

20.

Best S, Gubser P, Sethumadhavan S, Kersbergen A, Negron Abril Y, Goldford J . Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. Cell Metab. 2022; 34(6):874-887.e6. DOI: 10.1016/j.cmet.2022.04.003. View